Bempedoic Acid Mechanism of Action Paper Published in Nature Communications: Q&A with the Authors

December 2, 2016
Narendra Lalwani, PhD, MBA, FAHA
Executive Vice President, Research and Development, and Chief Operating Officer
Marianne Andreach
Senior Vice President, Strategic Marketing and Product Planning
Steve Pinkosky
Senior Scientist, Head of Translational Research

As you may have seen, Esperion scientists and collaborators recently published the definitive paper on the mechanism of action for bempedoic acid, “Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis,” in the journal Nature Communications. I sat down with authors and colleagues Narendra Lalwani and Steve Pinkosky to discuss our findings,… Read More

Highlights from the 2016 ESC Congress

September 2, 2016
Tim Mayleben
President and Chief Executive Officer
Marianne Andreach
Senior Vice President, Strategic Marketing and Product Planning

Buongiorno from the ESC Congress! Earlier this week we had the opportunity to attend the 2016 European Society of Cardiology (ESC) Congress in Rome. ESC has become the largest cardiology meeting in the world with more than 32,000 physicians and other healthcare care professionals in attendance this year. This is one of the most important… Read More